Perfluoro Curcumin Strongly Interacts with ABC Transporter (ABCG2): A Molecular Docking Study
Journal: Journal of Embryology & Stem Cell Research (JES) (Vol.2, No. 2)Publication Date: 2018-07-18
Authors : Raviteja CN Sharma S Bhardiya S Bhardwaj V Chandel V; Kumar D;
Page : 1-10
Keywords : ABCG2; Curcumin; Cancer Stem Cell; Molecular Docking;
Abstract
Cancer stem cells remain one of the most common reasons for drug resistance and therapeutic failure. The membrane transporter protein ABCG2 has been shown to be over expressed and efflux anti-cancer drugs from cancer stem cells. Despite therapeutic development, the cancer drug resistance and tumor recurrence have increased dramatically in last few years. Thus, identification of potential inhibitor for ABCG2 can be an effective therapeutic approach for cancer through targeting cancer stem cells. In this article, we have performed molecular docking between Curcumin derivatives and ABCG2. Perfluoro Curcumin out of 29 Curcumin derivatives showed highest binding energy, -10.1 kcal/mol with ABCG2, suggest that the Curcumin derivative can be used an effective inhibitor against ABCG2. Perfluoro Curcumin strongly interacted with the ABCG2 at their ligand binding site through hydrophobic interaction. These findings shed light on the molecular characteristics of the binding of Curcumin derivatives with ABCG2 and thus may significantly contribute in designing and optimizing therapeutic strategies against cancer through targeting cancer stem cells by using these agents
Other Latest Articles
- Role of Stem Cells in Cerebral Infarction
- The Role of β-catenin in Embryonic Stem Cell Maintenance Circuits and iPSCs - An International Systems Biology Approach of Open Science and Innovation
- Pressure Wounds and Skin Failure Secondary Scurvy. Prevention with Early Vitamin Micro Nutrient Supplements
- Analysis of the System of Cornea Donation in the State of Paraná in the Period from 2011 To 2016
- FOXP1 and ARID3A Collaborate to Activate Transcription of Core Embryonic Stem Cell Factors in Activated B-Cell Diffuse Large B cell Lymphoma
Last modified: 2019-06-15 19:13:22